Short-Chain Carboxylic Acids Modulating Regulatory T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and immune-mediated chronic inflammatory diseases, such as multiple sclerosis and Crohn's disease, are inadequate in modulating the immune response effectively, particularly in influencing the intestinal microbiome and regulatory T cells.
Innovation Solution
The use of short-chain C3-C8 carboxylic acids, such as propionic and butyric acid, and their physiologically acceptable salts and esters, which have immunomodulatory effects by promoting the proliferation of regulatory T cells and positively influencing the intestinal microbiome, thereby addressing the disease course in neurodegenerative and autoimmune conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for autoimmune diseases, then disease management is maintained, but immunomodulatory effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional immunosuppressive agents to short-chain carboxylic acids (C3-C8) with specific molecular characteristics. These compounds modify the immunomodulatory mechanism by targeting regulatory T cells and microbiome interactions, changing the therapeutic parameter from general suppression to targeted modulation, thereby improving effectiveness while maintaining reliability
2Object-generated harmful factors
If conventional immunosuppressive agents are used, then immune response is suppressed, but modulation of regulatory T cells and intestinal microbiome is insufficient
Solution Approach 1:
The patent applies local quality by targeting specific biological compartments and cell types with short-chain carboxylic acids. The compounds selectively modulate regulatory T cells in the intestines and blood, and specifically influence the intestinal microbiome composition, rather than causing broad immunosuppression. This localized action provides versatile modulation of immune and microbial systems simultaneously
3Use of energy by moving object
If long-chain fatty acids are administered, then energy provision is improved, but regulatory T cells and intestinal microbiota are inhibited
Solution Approach 1:
The patent applies inversion by reversing the chain length approach to fatty acid administration. Instead of using long-chain fatty acids (C12+) which provide energy but inhibit immune cells and microbiota, the invention uses short-chain carboxylic acids (C3-C8) that have the opposite effect - they promote regulatory T cell proliferation and enhance microbiota diversity while still providing metabolic benefits, thereby inverting the harmful relationship between energy provision and immune modulation
Data Source
AI summary
The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.